Compare Abeona Therapeutics Inc (ABEO) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lululemon Athletica Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Lululemon Athletica Inc trades at $121.31 (market cap $14.26B). The key difference: Lululemon Athletica Inc is far larger — about 33.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | LULU | |
|---|---|---|
Market Cap | $421.19M | $14.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $215.88 |
52-Week Low | $4.17 | $105.43 |
Enterprise Value | $276.10M | $14.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Lululemon stock trades at $120.88, down 5.41% amid broader market weakness in the premium apparel sector. The company maintains strong fundamentals with a P/E of 10.17, net income margin of 13.03%, and consistent earnings beats. Technical indicators show a bullish moving average trend despite overbought RSI readings, with key resistance near $129.
Investment outlook remains positive given undervaluation metrics and international growth potential, though risks include U.S. demand softness and competitive pressures. Analyst consensus targets $129.29 with 41% buy ratings, suggesting moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
